Johnson & Johnson $JNJ Shares Bought by TD Asset Management Inc

TD Asset Management Inc raised its holdings in Johnson & Johnson (NYSE:JNJ) by 2.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,558,541 shares of the company’s stock after acquiring an additional 35,409 shares during the quarter. TD Asset Management Inc’s holdings in Johnson & Johnson were worth $322,540,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. J.W. Cole Advisors Inc. increased its position in shares of Johnson & Johnson by 2.2% in the third quarter. J.W. Cole Advisors Inc. now owns 130,934 shares of the company’s stock valued at $24,278,000 after buying an additional 2,769 shares in the last quarter. Guinness Asset Management LTD increased its position in shares of Johnson & Johnson by 0.4% in the third quarter. Guinness Asset Management LTD now owns 1,383,195 shares of the company’s stock valued at $251,216,000 after buying an additional 5,994 shares in the last quarter. Greenberg Financial Group purchased a new position in shares of Johnson & Johnson in the fourth quarter valued at $954,000. Envestnet Asset Management Inc. increased its position in shares of Johnson & Johnson by 4.4% in the third quarter. Envestnet Asset Management Inc. now owns 5,135,378 shares of the company’s stock valued at $952,202,000 after buying an additional 214,830 shares in the last quarter. Finally, Varma Mutual Pension Insurance Co increased its position in shares of Johnson & Johnson by 8.9% in the third quarter. Varma Mutual Pension Insurance Co now owns 378,256 shares of the company’s stock valued at $70,136,000 after buying an additional 30,900 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.3%

Johnson & Johnson stock opened at $223.60 on Thursday. The stock has a market cap of $538.25 billion, a PE ratio of 25.85, a P/E/G ratio of 2.18 and a beta of 0.26. The stock has a 50-day moving average price of $232.25 and a 200 day moving average price of $225.69. Johnson & Johnson has a 52 week low of $149.04 and a 52 week high of $251.71. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping analysts’ consensus estimates of $2.68 by $0.02. The firm had revenue of $24.06 billion during the quarter, compared to analysts’ expectations of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The firm’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same quarter last year, the business posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Equities research analysts predict that Johnson & Johnson will post 11.57 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be issued a $1.34 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date is Tuesday, May 26th. This represents a $5.36 annualized dividend and a yield of 2.4%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 61.97%.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of research analyst reports. Johnson Rice upgraded Johnson & Johnson from a “hold” rating to an “outperform” rating in a research report on Wednesday, May 13th. Bank of America lifted their price objective on Johnson & Johnson from $253.00 to $254.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 15th. JPMorgan Chase & Co. lifted their price objective on Johnson & Johnson from $250.00 to $260.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 15th. Weiss Ratings cut Johnson & Johnson from a “buy (b+)” rating to a “buy (b)” rating in a research report on Friday, April 24th. Finally, Stifel Nicolaus lifted their price objective on Johnson & Johnson from $220.00 to $250.00 and gave the stock a “hold” rating in a research report on Wednesday, April 15th. Twenty equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $253.04.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported encouraging Phase 2 results for nipocalimab in lupus, meeting the primary endpoint and showing sustained disease activity reduction through 52 weeks. Article Title
• Positive Sentiment: New Sjögren’s disease data further reinforced nipocalimab’s ability to reduce autoantibodies and showed stronger response rates in patients with higher disease burden. Article Title
• Neutral Sentiment: Johnson & Johnson is drawing extra investor attention, likely reflecting renewed focus on the stock after the recent pipeline updates and broader interest in defensive healthcare names. Article Title
• Neutral Sentiment: Commentary on Johnson & Johnson as a potential high-growth dividend stock may be supporting the company’s income-investor appeal, but it does not appear to reflect a new operating development. Article Title
• Neutral Sentiment: Scotiabank reiterated a Buy rating on Johnson & Johnson, which can help reinforce confidence in the stock among investors. Article Title

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.